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Li–Fraumeni syndrome (LFS) is an autosomal, dominant, inher-
ited cancer disorder, characterized by a broad but specific
spectrum of tumours observed at an early age, in particular a
predominance of bone and soft tissue sarcomas, brain and breast
cancer (Li et al, 1988). LFS is defined by a strict clinical
definition, described previously (Li et al, 1988). This definition
has been relaxed to include Li–Fraumeni-like (LFL) cases (Birch
et al, 1994).
In 1990, the tumour suppressor gene TP53 was identified as the
candidate for mutation in a number of LFS families (Malkin et al,
1990). To date more than 50 families have been identified with
germline TP53 mutations (Varley et al, 1997a). Previously we
have detected mutations in approximately 70% of LFS and 20% of
LFL families, when all exons, including non-coding regions, have
been sequenced (Varley et al, 1997b). Therefore, 30% of LFS and
the majority of LFL families do not have a detectable germline
mutation within the coding region of TP53. The p53 protein
functions in checkpoint control at G1/S and G2 phase of the cell
cycle. It is feasible that characterization of related genes, for
example other cell cycle inhibitors, may identify germline muta-
tions within these families. We have selected genes for analysis
that are involved in p53-related pathways or are known to be
mutated in Li–Fraumeni-associated tumours, in particular the
tumour suppressor genes CDKN2, which encodes p16 and p19ARF,
and PTEN. Like p53, both p16 and p19ARF function as negative
regulators of the cell cycle, with the p16 gene shown to be mutated
in many tumour types (Kamb, 1995; Quelle et al, 1995). PTEN
mutations have also been observed in a number of tumours (Steck
et al, 1997). We have analysed 16 families, previously shown to be
negative for mutations to TP53 (Varley et al, 1997b), for mutations
to these sequences.
MATERIALS AND METHODS
Families were ascertained as previously described (Varley et al,
1997b). Blood samples were obtained from either the proband or a
first-degree relative in each family (Table 1). DNA was isolated
from whole blood using the Dynabeads DNA direct System
(Dynal), according to manufacturers instructions.
Genomic DNAs were amplified by nested polymerase chain
reaction (PCR) to generate products corresponding to each exon of
PTEN and  CDKN2. Primers and PCR conditions are available
from authors. PCR products were sequenced directly using either
an ABI377 Sequencer with Dye Primer chemistry (Perkin-Elmer
Applied Biosystems), or a Sequenase kit (USB).
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Table 1 Mutation analysis of PTEN and CDKN2 in LFS and LFL familiesa
Familyb Personb Mutation foundc
Nucleotide changed Amino acid change
LFS Families
22 III-5 None
81 III-5 None
82 IV-5 None
88 II-2 None
119 III-1 None
1779 III-7 None
LFL Families
80 V-4 None
253 IV-2 CDKN2 : 442 G>A p16: Alal48Thre
328 II-3 None
338 III-2 None
348 III-2 None
352 IV-1 None
353 III-3 None
2093 IV-3 None
2613 III-1 None
2634 III-3 None
aFor details of tumour types and relationship to proband in each family, refer
to Varley et al (1997b). bFamily and Person numbers are as previously
(Varley et al, 1997b). cIncludes mutations found in PTEN and CDKN2.
dNucleotide positions are derived from the amended p16 gene sequence
(Okamoto et al, 1994). eAla148Thr is a common polymorphism, previously
reported as Ala140Thr (Hussussian et al, 1994).RESULTS AND DISCUSSION
We report the results of sequencing six LFS and ten LFL samples
for mutations in tumour suppressor genes PTEN and CDKN2. The
CDKN2 gene consists of four exons (1a, 1b, 2 and 3), and encodes
two proteins: p16 and p19ARF. The p16 protein is encoded by exons
1a, 2 and 3, and functions as a negative regulator in the G1 phase
of the cell cycle. The p16 gene is a major target in carcinogenesis,
and has been shown to be inactivated in a number of tumour cell
lines and primary tumours including adenocarcinomas and
glioblastoma (Kamb, 1995). Germline mutations in the gene can
result in hereditary predisposition to the development of
melanoma and pancreatic cancer (Hussussian et al, 1994; Foulkes
et al, 1997). In addition, an alternatively spliced transcript,
encoding p19ARF, is derived from the same locus as p16 and
contains a novel first exon (1b), located upstream of exon 1a.
Both transcripts share exons 2 and 3 but are translated in a
different reading frame, and hence p16 and p19ARF have no amino
acid similarity. The p19ARF protein also functions to block cell
cycle progression at G1 and G2, although in a p53-dependent
manner (Quelle et al, 1995). We have been unable to identify any
germline mutations in either the p16 or p19ARF genes in the
Li–Fraumeni families tested, although we have detected a single
heterozygous polymorphism at codon 148 of p16 in IV-2, family
253 (Table 1). This polymorphism is prevalent in the population
(Hussussian et al, 1994), and has no effect on p19ARF.
The tumour suppressor gene PTEN (MMAC1) was isolated by
mapping of homozygous deletions commonly found in glioblast-
omas (Li et al, 1997). Subsequently somatic mutations in PTEN
have been observed in a number of tumours including breast and
brain tumours, and malignant melanoma (Steck et al, 1997).
Germline mutations in the gene have been identified in Cowden
syndrome, which is associated with early onset breast cancer (Tsou
et al, 1997). However, a recent study of 136 breast cancer families
has shown that PTEN is not linked to familial breast cancer (Chen
et al, 1998). The gene encodes a dual specificity phosphatase, with
enzymatic activity required for tumour suppressor function (Myers
et al, 1997). We have not detected any PTEN mutations in the
families analysed.
We have therefore excluded these genes as candidates for
mutation in Li–Fraumeni syndrome. However, this does not
preclude other cell cycle control genes as targets for mutation,
for example the Rb and p21 genes.
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